Volume 32, No 5, May 2022
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 32 Issue 5, May 2022: 423-424
Banking on metabolomics for novel therapies in TNBC
Aurelien Tripp , George Poulogiannis*Signalling and Cancer Metabolism Team, Division of Cancer Biology, The Institute of Cancer Research, London, UK
Despite sharing the lack of hormone receptors and HER2 amplification used to guide therapeutic decisions, Triple-Negative Breast Cancer (TNBC) is a highly heterogeneous subset of breast cancer. In a recent study published in Cell Research, Xiao et al. highlight the opportunity of using this tumor subtype’s metabolic signatures to better stratify patients and identify more effective therapeutic strategies in TNBC.